Research Progress and Challenges in the Use of TROP2-Targeted Antibody-Drug Conjugates for the Treatment of Triple-Negative Breast Cancer
DOI:
https://doi.org/10.54097/y20f7729Keywords:
Triple-negative Breast Cancer, TROP2, Antibody-drug Conjugates, Mechanisms of ResistanceAbstract
Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression, has long been associated with limited treatment targets, a high risk of recurrence and metastasis, and a poor prognosis. In recent years, antibody-drug conjugates (ADCs), which link targeted antibodies to cytotoxic payloads, have provided a new avenue for breakthroughs in precision therapy for TNBC. TROP2 is highly expressed in various epithelial tumors and is associated with tumor invasion, metastasis, and poor prognosis; it has thus become a key target for TNBC-ADC drug development. Existing studies indicate that TROP2-ADCs, represented by Sacituzumab Govitecan (SG), can improve treatment outcomes for patients with advanced TNBC; however, challenges remain, including unclear mechanisms of resistance, a lack of biomarkers, difficulties in managing adverse reactions, and insufficient evidence for specific patient populations. Future efforts should focus on further optimizing ADC structures, refining TROP2 detection standards, and exploring personalized combination therapy strategies to advance the development of precision medicine for TNBC. This article provides a review of the fundamental mechanisms, clinical research progress, challenges in clinical application, and future directions for TROP2-ADC drugs in the treatment of TNBC.
Downloads
References
[1] Zagami, P., & Carey, L. A. (2022). Triple negative breast cancer: Pitfalls and progress. npj Breast Cancer, 8(1), 95. https://doi.org/10.1038/s41523-022-00468-0 DOI: https://doi.org/10.1038/s41523-022-00468-0
[2] de Ruijter, T. C., Veeck, J., de Hoon, J. P. J., van Engeland, M., & Tjan Heijnen, V. C. (2011). Characteristics of triple negative breast cancer. Journal of Cancer Research and Clinical Oncology, 137(2), 183–192. https://doi.org/10.1007/s00432-010-0957-x DOI: https://doi.org/10.1007/s00432-010-0957-x
[3] Rakha, E. A., Tse, G. M., & Quinn, C. M. (2023). An update on the pathological classification of breast cancer. Histopathology, 82(1), 5–16. https://doi.org/10.1111/his.14786 DOI: https://doi.org/10.1111/his.14786
[4] Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023). Deciphering breast cancer: From biology to the clinic. Cell, 186(3), 528–544. https://doi.org/10.1016/j.cell.2023.01.011 DOI: https://doi.org/10.1016/j.cell.2023.01.040
[5] Lebedeva, V., Ebbinghaus, M., Hidalgo, J. V., Hardt, O., & Pfeifer, R. (2025). Triple Negative Breast Cancer Unveiled: Bridging science, treatment strategy, and economic aspects. International Journal of Molecular Sciences, 26(19), 9714. https://doi.org/10.3390/ijms26199714 DOI: https://doi.org/10.3390/ijms26199714
[6] Katheeja, M. N., Das, S. P., Das, R., & Laha, S. (2023). BRCA1 interactors, RAD50 and BRIP1, as prognostic markers for triple negative breast cancer severity. Frontiers in Genetics, 14. https://doi.org/10.3389/fgene.2023.1035052 DOI: https://doi.org/10.3389/fgene.2023.1035052
[7] Shvartsur, A., & Bonavida, B. (2015). Trop2 and its overexpression in cancers: Regulation and clinical/therapeutic implications. Genes & Cancer, 6(3 4), 84–105. https://doi.org/10.18632/genesandcancer.40 DOI: https://doi.org/10.18632/genesandcancer.40
[8] Sakach, E., Sacks, R., & Kalinsky, K. (2022). Trop 2 as a therapeutic target in breast cancer. Cancers, 14(23), 5936. https://doi.org/10.3390/cancers14235936 DOI: https://doi.org/10.3390/cancers14235936
[9] Vidula, N., Yau, C., & Rugo, H. (2022). Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Research and Treatment, 194(3), 569–575. https://doi.org/10.1007/s10549-022-06660-x DOI: https://doi.org/10.1007/s10549-022-06660-x
[10] Izci, H., Punie, K., Waumans, L., Van den Eynden, G., Van Laere, S., & Van Dam, P. A. (2022). Correlation of TROP 2 expression with clinical pathological characteristics and outcome in triple negative breast cancer. Scientific Reports, 12(1), 19248. https://doi.org/10.1038/s41598-022-27093-y DOI: https://doi.org/10.1038/s41598-022-27093-y
[11] Morgenstern Kaplan, D., Kareff, S. A., Trabolsi, A., Narayan, P., Moulder, S., & Abramson, V. (2024). Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. The Oncologist, 29(11), e1480–e1491. https://doi.org/10.1093/oncolo/oyae168 DOI: https://doi.org/10.1093/oncolo/oyae168
[12] Jacot, W., Chateau, M. C., Thezenas, S., Cayre, G., Lamy, P. J., & Romieu, G. (2025). Prognostic value of Trop 2 expression in nonmetastatic triple negative breast cancer and correlation with emerging biomarkers. Cancer Medicine, 14(11), e70615. https://doi.org/10.1002/cam4.70615 DOI: https://doi.org/10.1002/cam4.70615
[13] Jabbarzadeh Kaboli, P., Shabani, S., Sharma, S., Partovi Nasr, M., Yamaguchi, H., & Hung, M. C. (2022). Shedding light on triple negative breast cancer with Trop2 targeted antibody drug conjugates. American Journal of Cancer Research, 12(4), 1671–1685.
[14] Hu, Y., Zhu, Y., Qi, D., Tang, C., & Zhang, W. (2024). Trop2 targeted therapy in breast cancer. Biomarker Research, 12(1), 58. https://doi.org/10.1186/s40364-024-00633-6 DOI: https://doi.org/10.1186/s40364-024-00633-6
[15] Hoffmann, R. M., Coumbe, B. G. T., Josephs, D. H., Meleady, R., Fletcher, E., & Spicer, J. F. (2018). Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). OncoImmunology, 7(3), e1395127. https://doi.org/10.1080/2162402X.2017.1395127 DOI: https://doi.org/10.1080/2162402X.2017.1395127
[16] García Alonso, S., Ocaña, A., & Pandiella, A. (2018). Resistance to Antibody–Drug Conjugates. Cancer Research, 78(9), 2159–2165. https://doi.org/10.1158/0008-5472.CAN-17-3671 DOI: https://doi.org/10.1158/0008-5472.CAN-17-3671
[17] Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loong, F., Chan, A., & Modi, S. (2021). Sacituzumab Govitecan in Metastatic Triple Negative Breast Cancer. The New England Journal of Medicine, 384(16), 1529–1541. https://doi.org/10.1056/NEJMoa2028485 DOI: https://doi.org/10.1056/NEJMoa2028485
[18] Thomas, A., & Pommier, Y. (2019). Targeting topoisomerase I in the era of precision medicine. Clinical Cancer Research, 25(22), 6581–6589. https://doi.org/10.1158/1078-0432.CCR-19-1089 DOI: https://doi.org/10.1158/1078-0432.CCR-19-1089
[19] Jiang, K., & Wang, S. (2026). Advances in TROP2 targeted antibody drug conjugates for breast cancer therapy: Into the new era. Cancer Biology & Medicine, 23(3), 327–337. https://doi.org/10.20892/j.issn.2095-3941.2025.0504 DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0504
[20] Bardia, A., Krop, I. E., Kogawa, T., Moore, H. C., O’Shaughnessy, J., & Moore, K. N. (2024). Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple Negative Breast Cancer: Results From the Phase I TROPION PanTumor01 Study. Journal of Clinical Oncology, 42(19), 2281–2294. https://doi.org/10.1200/JCO.23.01909 DOI: https://doi.org/10.1200/JCO.23.01909
[21] Sofianidi, A. A., Papatheodoridi, A., Dimitrakakis, C., Marinopoulos, S., Michalaki, V., & Zagouri, F. (2025). Sacituzumab tirumotecan (sac TMT/MK 2870/SKB264): A novel antibody–drug conjugate in breast cancer. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1291669 DOI: https://doi.org/10.3389/or.2026.1781533
[22] Dent, R. A., Hui, R., Park, Y. H., Barrios, C., Kim, S. B., & Im, S. A. (2024). A phase III, randomized study of adjuvant sacituzumab tirumotecan plus pembrolizumab vs treatment of physician’s choice in patients with TNBC who received neoadjuvant therapy and did not achieve pCR at surgery. Annals of Oncology, 35(Suppl 11), S1413. https://doi.org/10.1016/j.annonc.2024.10.044 DOI: https://doi.org/10.1016/j.annonc.2024.10.044
[23] Liu, X., Ma, L., Li, J., Zhou, Y., Wang, Y., & Zhao, J. (2024). Trop2 targeted therapies in solid tumors: Advances and future directions. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1404821 DOI: https://doi.org/10.7150/thno.98178
[24] Eroles, P., Dawid de Vera, M. T., & Lago, V. (2025). TROP2 targeting antibody–drug conjugates in breast cancer and ovarian carcinoma: Therapeutic advances and resistance mechanisms. Clinical Drug Research, 195. https://doi.org/10.12688/cdr.2025.195 DOI: https://doi.org/10.20517/cdr.2025.195
[25] Coates, J. T., Sun, S., Leshchiner, I., Helman, E., Miller, M., & Wagle, N. (2021). Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple negative breast cancer. Cancer Discovery, 11(10), 2436–2445. https://doi.org/10.1158/2159-8290.CD-21-0068 DOI: https://doi.org/10.1158/2159-8290.CD-21-0702
[26] Xiong, X., Zheng, L. W., Ding, Y., Li, X., Chen, L., & Zhang, Y. (2024). Breast cancer: Pathogenesis and treatments. Signal Transduction and Targeted Therapy, 9(1), 287. https://doi.org/10.1038/s41392-024-02108 x DOI: https://doi.org/10.1038/s41392-024-02108-4
[27] Ye, L., Chen, H., & Wu, D. (2025). TROP2 targeted molecular imaging: A promising tool for precision oncology. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1327709 DOI: https://doi.org/10.62347/BKIS3836
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
